Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Nat Rev Neurol. 2017 Apr 18;13(5):265–278. doi: 10.1038/nrneurol.2017.45

Figure 1.

Figure 1

Experimental workflow for hiPSC models of neurodevelopmental disorders. Different experimental options are shown with regards to type of controls (cross-sectional, matched pair or family contrpol), choice of reprogrammed cell type, type of differentiation protocol, and outcome metrics. For patients with X-linked disorders, different colored cells represent cells with either the wild type or the mutated X allele. Corrected cells represent the same patient-derived cells after genome editing or drug treatment.